FDA and M-CERSI Launch Two-Day Workshop to Accelerate Pediatric SLE Drug Development in 2026

With only one biologic approved for pediatric systemic lupus erythematosus, the FDA is signaling a sharper regulatory focus on extrapolation strategies and innovative trial designs that sponsors in autoimmune indications will need to understand before submitting pediatric development plans. The agency, alongside the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI), will host a two-day workshop on July 30–31, 2026, at the FDA White Oak Campus in Silver Spring, MD, with concurrent webcast access.

The workshop centers on the disease-specific challenges that make pediatric SLE trials structurally difficult: a small eligible patient population, limited specialized clinical centers, and persistent recruitment and retention barriers. Approximately 10–20% of SLE cases present during childhood, yet the therapeutic landscape for that cohort remains critically thin. For regulatory affairs leads preparing pediatric investigation plans or responding to agency requests under 21 CFR Part 314 Subpart I and the Pediatric Research Equity Act, the workshop's extrapolation framework discussions carry direct submission implications.

The central technical question the FDA is putting to stakeholders is how adult SLE trial data can be appropriately leveraged to support pediatric indications without requiring full parallel trial programs. Extrapolation methodology, when accepted by the agency, can reduce both the clinical burden on a small patient population and the development timeline for sponsors. The workshop will draw researchers, clinicians, patient advocates, and industry representatives into structured dialogue intended to shape how the agency evaluates these strategies going forward.

For biologics and small-molecule sponsors already in late-stage adult SLE programs, the workshop represents an early-signal opportunity: the agency's stated intent to improve efficiency and feasibility in pediatric SLE studies suggests that sponsors who engage now, and align their pediatric development assumptions with emerging FDA thinking, will be better positioned when formal guidance follows. Regulatory affairs teams should treat the published agenda and any resulting workshop proceedings as reference material for pediatric study protocol design and extrapolation justification sections in future submissions.

Registration is open for both in-person attendance at Building 31, Room 1503, and virtual participation via webcast; the first day runs 9:00 a.m. to 5:00 p.m. ET and the second concludes at 12:30 p.m. ET.

The proceedings and any draft recommendations emerging from the July sessions will serve as a measurable indicator of how the FDA intends to operationalize pediatric extrapolation standards for autoimmune indications in the near-term review cycle.

Source: FDA Drugs News and Events via FDA.gov RSS Feed, published June 5, 2026; event scheduled July 30–31, 2026.